The purpose of this study was to compare the efficacy of two regimens of intravenous iron sucrose [continuous (in every hemodialysis session) versus intermittent (every 1-4 weeks)] on the response of rHuEPO in the maintenance phase of its administration in hemodialysis patients.

Inclusion Criteria:

• Constant rHu-EPO and iron dose for at least 2 months before starting the study
• Hemoglobin ≥ 8,5g/dl and <12,5 g/dl
• Ferritin < 1000 mg/dl
• TSAT < 50%
• CRP < 5 mg/dl

Exclusion Criteria:

• Malignant tumor disease
• Oral iron supplementation
• Active bleeding issues
• Surgical intervention within the last 8 weeks before study inclusion